The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives

Journal of Human Hypertension

Volumn 25, Issue 9, 2011, Pages 554-559

  Tsioufis, C ^a   Kyvelou, S ^a   Dimitriadis, K ^a   Syrseloudis, D ^a   Sideris, S ^a   Skiadas, I ^a   Katsi, V ^a   Stefanadi, E ^a   Lalos, S ^a   Mihas, C ^a   Poulakis, M ^a   Stefanadis, C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

adiponectin; arterial stiffness; C reactive protein; serum uric acid

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; URIC ACID;

ADULT; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY PULSE; CORRELATION ANALYSIS; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; FEMORAL ARTERY; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; REGRESSION ANALYSIS; URIC ACID; VASCULAR STIFFNESS;

EID: 80052038244     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.98     Document Type: Article

References (29)

1. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457-464.
2. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent developments and where do they leave us? Am J Med 2005; 118: 816-826.
3. Short RA, Johnson RJ, Tuttle KR. Uric acid, microalbuminuria and cardiovascular events in high-risk patients. Am J Nephrol 2005; 25: 36-44.
4. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: The PIUMA study. Hypertension 2000; 36: 1072-1078.
5. Sakata K, Hashimoto T, Ueshima H, Okayama A, NIPPON DATA 80 Research Group. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National integrated projects for prospective observation of noncommunicable diseases and its trend in the aged. Eur J Epidemiol 2001; 17: 461-468.
6. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: 991-997.
7. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor a-chain expression. J Biol Chem 1991; 266: 8604-8608.
8. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247.
9. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26: 269-275.
10. Kanellis J,Watanabe S, Li JH, Kang DH, Li P, Nakagawa T et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-1293.
11. Tsioufis C, Dimitriadis K, Andrikou E, Thomopoulos C, Tsiachris D, Stefanadi E et al. ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: A cross-sectional study. Am J Kidney Dis 2010; 55: 1050-1059.
12. Tsioufis C, Dimitriadis K, Selima M, Thomopoulos C, Mihas C, Skiadas I et al. Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J 2007; 28: 1162-1169.
13. Feig DI, Kang D-H, Johnson RJ. Uric acidand cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
14. Tsioufis C, Chatzis D, Vezali E, Dimitriadis K, Antoniadis D, Zervoudaki A et al. The controversial role of serum uric acid in essential hypertension: Relationships with indices of target organ damage. J Hum Hypertens 2005; 19: 211-217.
15. Tsioufis C, Stefanadis C, Antoniadis D, Kallikazaros I, Zambaras P, Pitsavos C et al. Absence of any significant effects of circadian blood pressure variations on carotid artery elastic properties in essential hypertensive subjects. J Hum Hypertens 2000; 14: 813-818.
16. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of the left ventricular dimensions by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of the two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
17. Tsioufis C, Chatzis D, Dimitriadis K, Stougiannos P, Kakkavas A, Vlasseros I et al. Left ventricular diastolic dysfunction is accompanied by increased aortic stiffness in the early stages of essential hypertension: A TDI approach. J Hypertens 2005; 23: 1745-1750.
18. Netea MG, Kullberg BJ, Block WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997; 89: 577-582.
19. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
20. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457.
21. Teijeira-Fernandez E, Eiras S, Grigorian-Shamagian L, Fernandez A, Adrio B, Gonzalez-Juanatey JR. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. J Hum Hypertens 2008; 22: 856-863.
22. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002; 10: 1104-1110.
23. Gonzaĺez-Sańchez JL, Zabena CA, Martińez-Larrad MT, Fernańdez-Peŕez C, Peŕez-Barba M, Laakso M et al. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. Obes Res 2005; 13: 807-812.
24. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci 2002; 103: 137-142.
25. Fessel WJ. High uric acid as an indicator of cardiovascular disease. Am J Med 1980; 68: 401-404.
26. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. Am J Epidemiol 1995; 141: 637-644.
27. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000; 10: 136-143.
28. Tomiyama H, Kushiro T, Okazaki R, Yoshida H, Doba N, Yamashina A. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement a survey of 12517 subjects. Atherosclerosis 2003; 166: 303-309.
29. Cuspidi C, Valerio C, Sala C, Meani S, Esposito A, Zanchetti A et al. Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens 2007; 20: 678-685.